ATOS Atossa Genetics Inc.

Registration Is Now Open For Tribe Public’s Webinar Event “The Important Role of COVID Therapeutics in a Post-Vaccine World” Featuring Atossa Therapeutics’ CEO & CFO On February 2, 2021

Registration Is Now Open For Tribe Public’s Webinar Event “The Important Role of COVID Therapeutics in a Post-Vaccine World” Featuring Atossa Therapeutics’ CEO & CFO On February 2, 2021

Meet With Atossa’s CEO Dr. Steven Quay, M.D., Ph.D. & CFO Kyle Guse who will deliver a presentation titled “The Important Role of COVID Therapeutics in a Post Vaccine World”

SEATTLE, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announces that Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D. & CFO, Kyle Guse, Esq., will present at Tribe Public’s Webinar Presentation and Q&A Event titled “The Important Role of COVID Therapeutics in a Post Vaccine World”. The Event is scheduled to begin at 8am Pacific/11am Eastern on Tuesday, February 2, 2021.

To register to join the complimentary, ZOOM webinar-based event, please visit Tribe Public LLC at .

Once registered, participants may begin forwarding their questions for Atossa’s management to Tribe Public at or share their questions via the ZOOM chat feature during the event. Tribe Public’s Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.

Steven Quay, M.D., Ph.D. Background

Steven Quay, M.D., Ph.D. is the founder of Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS). He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital and spent almost a decade on the faculty of Stanford University’s School of Medicine. His contributions to medicine have been cited 9,890 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented. His current passions are solving big medical problems: stopping the COVID-19 pandemic and preventing the two million breast cancer cases in the world each year. A Free copy of Dr. Quay’s best-selling and highly acclaimed book titled “Stay Safe: A Physician’s Guide to the Coronavirus” will be sent to all participants of the Feb. 2, 2021 Tribe Public Event upon request.

ABOUT ATOSSA THERAPEUTICS



Seattle-based Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit .



ABOUT TRIBE PUBLIC LLC



Tribe Public LLC is a San Francisco, CA-based organization that hosts complimentary worldwide webinar & meeting events in the U.S. Tribe's events focus on issues that the Tribe's members care about with an emphasis on hosting management teams and experts from publicly traded companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress, and plans. Tribe members primarily include Institutions, Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media. Tribe Members are encouraged to express their interest in speakers at the Tribe Public website via the Tribe's FREE "Wish List" process. Visit Tribe Public's Website  to join the Tribe and express your interests today.

Company Contact:

Atossa Therapeutics, Inc.

Kyle Guse, CFO and General Counsel

Office: 866 893-4927

Investor Relations Contact:

Core IR

Office:(516) 222-2560

A photo accompanying this announcement is available at



EN
27/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Atossa Genetics Inc.

Atossa Therapeutics Inc: 1 director

A director at Atossa Therapeutics Inc maiden bought 25,000 shares at 1.770USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...

 PRESS RELEASE

Atossa Therapeutics Announces First Quarter 2023 Financial Results and...

Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update Two Phase 2 trials investigating (Z)-endoxifen in neoadjuvant setting initiated and are enrolling patientsFull enrollment of Phase 2 KARISMA mammographic breast density study expected by end of 2023Ended first quarter 2023 with $103.9 million of cash and cash equivalents and no debt SEATTLE, May 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs...

 PRESS RELEASE

Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast...

Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces that a Trial in Progress poster for the Phase 2 clinical study of (Z)-endoxifen in premenopausal women with early stage ER+ / HER2- brea...

 PRESS RELEASE

Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Re...

Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment” Virtual webinar scheduled for Thursday, May 4 at 8:00 am pacific / 11:00 am easternMeet with Atossa’s Founder and CEO, Steven Quay, M.D., Ph.D.Event is open to the public – registration available at ATOS5423.TribePublic.com SEATTLE, April 27, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in oncology with a current focus on breast c...

 PRESS RELEASE

Atossa Therapeutics Announces Year-End 2022 Financial Results and Prov...

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced financial results for the fiscal quarter and fiscal year ended December 31, 2022 and provided an update on recent company developments. Key developments from Q4 2022 and year to date include: Initiation and First Patient Dosed in Phase 2 EVANGELINE Study – EVANGELIN...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch